Trop2 is overexpressed in gastric cancer and predicts poor prognosis

Oncotarget

Volumn 7, Issue 5, 2016, Pages 6136-6145

  Zhao, Wei ^a,b   Zhu, Huijun ^b   Zhang, Shu ^b   Yong, Hongmei ^c   Wang, Wei ^b   Zhou, Yan ^d   Wang, Bing ^d   Wen, Jinbo ^a   Qiu, Zhenning ^a   Ding, Guipeng ^a   Feng, Zhenqing ^a   Zhu, Jin ^a,e  

^a NANJING MEDICAL UNIVERSITY   (China)

^b NANTONG UNIVERSITY   (China)

^c XUZHOU MEDICAL UNIVERSITY   (China)

^d Aoyang Hospital Affiliated to Jiangsu University   (China)

^e Huadong Medical Institute of Biotechniques   (China)

Author keywords

Gastric cancer; Prognosis; Trop2

Indexed keywords

CELL SURFACE PROTEIN; MESSENGER RNA; TROP2 PROTEIN; UNCLASSIFIED DRUG; CELL ADHESION MOLECULE; TACSTD2 PROTEIN, HUMAN; TUMOR ANTIGEN; TUMOR MARKER;

ADULT; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CHINESE; CONTROLLED STUDY; DISTANT METASTASIS; FEMALE; GENE EXPRESSION; HELICOBACTER INFECTION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; STOMACH CANCER; TISSUE MICROARRAY; TUMOR DIFFERENTIATION; TUMOR VOLUME; BIOSYNTHESIS; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; PROCEDURES; PROGNOSIS; STOMACH TUMOR; SURVIVAL ANALYSIS;

ANTIGENS, NEOPLASM; BIOMARKERS, TUMOR; CELL ADHESION MOLECULES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; TISSUE ARRAY ANALYSIS;

EID: 84958068804     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.6733     Document Type: Article

References (48)

1. Du M, Wang W, Jin H, Wang Q, Ge Y, Lu J, Ma G, Chu H, Tong N, Zhu H, Wang M, Qiang F, Zhang Z. The association analysis of lncRNA HOTAIR genetic variants and gastric cancer risk in a Chinese population. Oncotarget. 2015; 6:31255-62. doi:10.18632/oncotarget.5158.
2. Liu L, Chen Q, Lai R, Wu X, Liu F, Xu G, Ji Y. Elevated expression of mature miR-21 and miR-155 in cancerous gastric tissues from Chinese patients with gastric cancer. J Biom Res. 2010; 24:187-197.
3. Sun R, Wang X, Zhu H, Mei H, Wang W, Zhang S, Huang J. Prognostic value of LAMP3 and TP53 overexpression in benign and malignant gastrointestinal tissues. Oncotarget. 2014; 5:12398-12409. doi:10.18632/oncotarget.2643.
4. Yoon H, Kim N. Diagnosis and management of high risk group for gastric cancer. Gut and liver. 2015; 9:5-17.
5. Choi YJ, Kim NY, Chang HY, Lee HS, Park SM, Park JH, Shin CH, Kim JM, Kim JS, Lee DH, Jung HC. Helicobacter pylori-induced epithelial-mesenchymal transition, a potential role of gastric cancer initiation and an emergence of stem cells. Carcinogenesis. 2015; 36:553-563.
6. Soichiro S, Wataru S, Shin M. Helicobacter pylori-Induced Signaling Pathways contribute to Intestinal Metaplasia and Gastric Carcinogenesis. Biom Res Int. 2015; 22: 737621-737629.
7. Park YH, Kim N. Review of atrophic gastritis and intestinal metaplasia as a premalignant lesion of gastric cancer. J Cancer Prev. 2015; 20:25-40.
8. Sue S, Shibata W, Maeda S. Helicobacter pylori-Induced Signaling Pathways Contribute to intestinal Metaplasia and Gastric Carcinogenesis. Bio Med Res Int. 2015; 2015: 737621.
9. Lin JC, Wu YY, Wu, JY, Lin TC, Wu CT, Chang YL, Jou YS, Hong TM, Yang PC. TROP2 is epigenetically inactivated and modulates IGF-1R signalling in lung adenocarcinoma. EMBO Mol Med. 2012; 4:472-485.
10. Wanger TM, Dewitt S, Collins A, Maitland NJ, Poghosyan Z, Knauper V. Differential regulation of TROP2 release by PKC isoforms through vesicles and ADAM17. Cell Signal. 2015; 27:1325-1335.
11. Cubas R, Li M, Chen C, Yao Q. Trop2: a possible therapeutic target for late stage epithelial carcinomas. Biochimica et Biophysica Acta. 2009; 1796:309-314.
12. Tsujikawa M, Kurahashi H, Tanaka T, Nishida K, Shimomura Y, Tano Y, Nakamura Y. Identification of the gene responsible for gelatinous drop-like corneal dystrophy. Nat Genet. 1999; 21:420-423.
13. Fong D, Spizzo G, Gostner JM, Gastl G, Moser P, Krammel C, Gerhard S, Rasse M, Laimer K. TROP2: a novel prognostic marker in squamous cell carcinoma of the oral cavity. Mod path. 2008; 21:186-191.
14. Muhlmann G, Spizzo G, Gostner J, Zitt M, Maier H, Moser P, Gastl G, Muller HM, Margreiter R, Ofner D, Fong D. TROP2 expression as prognostic marker for gastric carcinoma. J Clin Path. 2009; 62:152-158.
15. Wu H, Xu H, Zhang S, Wang X, Zhu H, Zhang H, Zhu J, Huang J. Potential therapeutic target and independent prognostic marker of TROP2 in laryngeal squamous cell carcinoma. Head & Neck. 2013; 35:1373-1378.
16. Wang JB, Zhang KH, Grabowska D, Li AM, Dong YY, Day R, Humphrey P, Lewis J, Kladney RD, Arbeit JM, Weber JD, Chung CH, Michel LS. Loss of Trop2 Promotes Carcinogenesis and Features of Epithelial to Mesenchymal Transition in Squamous cell Carcinoma. Mol Cancer Res. 2011; 9:1686-1695.
17. Zhang L, Zhou W, Velculescu VE, Kern SE, Hruban RH, Hamilton SR, Vogelstein B, Kinzler KW. Gene expression profiles in normal and cancer cells. Science. 1997; 276:1268-1272.
18. Lin H, Huang JF, Qiu JR, Zhang HL, Tang XJ, Li H, Wang CJ, Wang ZC, Feng ZQ, Zhu J. Significantly upregulated TACSTD2 and Cyclin D1 correlate with poor prognosis of invasive ductal breast cancer. Exp Mol Path. 2013; 94: 73-78.
19. Agboola AJ, Paish EC, Rakha EA, Powe DG, Macmillan RD, Ellis IO, Green AR. EpCAM expression is an indicator of recurrence in basal-like breast cancer. Breast Cancer Res Treat. 2012; 133:575-582.
20. Benko G, Spajic B, Kruslin B, Tomas D. Impact of the EpCAM expression on biochemical recurrence-free survival in clinically localized prostate cancer. Urol Oncol. 2013; 31: 468-474.
21. Tena-Suck ML, Ortiz-Plata A, Galan F, Sanchez A. Expression of epithelial cell adhesion molecule and pituitary tumor transforming gene in adamantinomatous craniopharyngioma and its correlation with recurrence of the tumor. Ann Diag Path. 2009; 13:82-88.
22. Stepan LP, Trueblood ES, Hale K, Babcook J, Borges L, Sutherland CL. Expression of Trop2 cell surface glycoprotein in normal and tumor tissues: potential implications as a cancer therapeutic target. J Histochem Cytochem. 2011; 59:701-710.
23. Fang YJ, Lu ZH, Wang GQ, Pan ZZ, Zhou ZW, Yun JP, Zhang MF, Wan DS. Elevated expressions of MMP7, TROP2, and survivin are associated with survival, disease recurrence, and liver metastasis of colon cancer. Int J Colorectal Dis. 2009; 24:875-884.
24. Wang H, Liu QQ, Tang XJ, Xu X, Chu C, Xiong SP, Zheng F, Tong H, Zhu J, Feng ZQ, Lin H. Eukaryotic expression of human anti-TROP2 antibody IgG, its inhibitory effect on cell proliferation of pancreatic cancer. Acta Univ Med Nanjing. 2014; 863-869+882.
25. Liu T, Liu Y, Bao X, Tian J, Yang X. Overexpression of TROP2 predicts poor prognosis of patients with cervical cancer and promotes the proliferation and invasion of cervical cancer cells by regulating ERK signaling pathway. PloS One. 2013; 8:e75864.
26. Shvartsur A, Bonavida B. Trop2 and its overexpression in cancers: regulation and clinical/therapeutic implications. Genes & cancer. 2015; 6:84-105. doi:10.18632/genesandcancer.40.
27. Lin H, Zhang HL, Wang J, Lu MP, Zheng F, Wang CJ, Tang XJ, Xu N, Chen RJ, Zhang DW, Zhao P, Zhu J, Mao Y, et al. A novel human Fab antibody for Trop2 inhibits breast cancer growth in vitro and in vivo. Int J Cancer. 2014; 134:1239-1249.
28. Wang H, Liu QQ, Tang XJ, Xu X, Chu C, Xiong SP, Zheng F, Tong H, Zhu J, Feng ZQ, Lin H. Eukaryotic expression of human anti-TROP2 antibody IgG and its inhibitory effect on cell proliferation of pancreatic cancer. Acta Univ Med Nanjing. 2014; (07):863-869+882.
29. Liang J, Liu QQ, Zhang H, Lin H, Tang Q, Liu Y, Su YP, Feng ZQ, Zhu J. Preparation and immunologic characterization of a monoclonal antibody against human trophoblast cell-surface antigen 2. Acta Univ Med Nanjing. 2011; (05):645-650.
30. Lin H, Zhang HL, Liang J, Zhu J, Tang Q, SU YP, Feng ZQ, Guan XH. Expression and characterization of Trop-2 extracellular domain protein of tumor relative antigen. Acta Univ Med Nanjing. 2010; (03):312-315.
31. Wang XY, Lin H, Zhang HH, Qiu JR, Ding GP, Tang XJ, Chen XM, Tang T, Liu QQ, Feng ZQ, Zhu J. Preparation and optimization of human anti-Trop-2 antibody fragment Fab. Acta Univ Med Nanjing. 2012; (01):35-39.
32. Vidmar T, Pavsic M, Lenarcic B. Biochemical and preliminary X-ray characterization of the tumor-associated calcium signal transducer 2 (Trop2) ectodomain. Protein Exp and Pur. 2013; 91:69-76.
33. Huang H, Groth J, Sossey-Alaoui K, Hawthorn L, Beall S, Geradts J. Aberrant expression of novel and previously described cell membrane markers in human breast cancer cell lines and tumors. Clin Cancer Res. 2005; 11: 4357-4364.
34. Guerra E, Trerotola M, Dell' Arciprete R, Bonasera V, Palombo B, El-Sewedy T, Ciccimarra T, Crescenzi C, Lorenzini F, Rossi C, Vacca G, Lattanzio R, Piantelli M, et al. A bicistronic CYCLIN D1-TROP2 mRNA chimera demonstrates a novel oncogenic mechanism in human cancer. Cancer Res. 2008; 68:8113-8121.
35. Lin JC, Wu YY, Wu JY, Lin TC, Wu CT, Chang YL, Jou YS, Hong TM, Yang PC. TROP2 is epigenetically inactivated and modulates IGF-1R signalling in lung adenocarcinoma. EMBO Mol Med. 2012; 4:472-485.
36. Lin ZS, Li Q. The latest 2010 WHO classification of tumors of digestive system. Zhonghua Bing Li Xue Za Zhi. 2011; 40:351-4.
37. Yu Sk, Lenz HJ. Molecular Classification of Gastric Adenocarcinoma: Translating New Insights from The Cancer Genome Atlas Research Network. Curr Treat. Options in Oncol. 2015; 16:17.
38. Qiu M, Zhou Y, Zhang X, Wang Z, Wang F, Shao J, Lu J, Jin Y, Wei X, Zhang D, Wang F, Li Y, Yang D1, Xu R. Lauren classification combined with HER2 status is a better prognostic factor in Chinese gastric cancer patients. BMC Cancer. 2014; 7:823.
39. Stiekema J, Cats A, Kuijpers A, van Coevorden F, Boot H, Jansen EP, Verheij M, Balague Ponz O, Hauptmann M, van Sandick JW. Surgical treatment results of intestinal and diffuse type gastric cancer. Implications for a differentiated therapeutic approach? Eur J Surg Oncol. 2013; 39:686-93.
40. Sun P, Du J, Zhu X, Ren C, Xie L, Dai N, Gu Y, Yan C, Dai J, Ma H, Jiang Y, Chen J, Hu Z, et al. Genetic Variation in the 3'-Untranslated Region of NBN Gene Is Associated with Gastric Cancer Risk in a Chinese Population. Plos One. 2015; 10:e0139059.
41. Park YH, Kim N. Review of atrophic gastritis and intestinal metaplasia as a premalignant lesion of gastric cancer. J Cancer Prev. 2015; 20:25-40.
42. Huang H, Wu J, Jin G, Zhang H, Ding Y, Hua Z, Zhou Y, Xue Y, Lu Y, Hu Z, Xu Y, Shen H. A 5'-flanking region polymorphism in toll-like receptor 4 is associated with gastric cancer in a Chinese population. J Biom Res. 2010; 24:100-106.
43. Detre S, Saclani Jotti G, Dowsett M. A "quickscore" method for immunohistochemical semiquantitation: validation for oestrogen receptor in breast carcinomas. J Clin Path. 1995; 48:876-878.
44. Tang Q, Liu YF, Zhu XJ, Li YH, Zhu J, Zhang JP, Feng ZQ, Guan XH. Expression and prognostic significance of the alpha B-crystallin gene in human hepatocellular carcinoma. Human Path. 2009; 40:300-305.
45. Han L, Jiang B, Wu H, Wang X, Tang X, Huang J, Zhu J. High expression of CXCR2 is associated with tumorigenesis, progression, and prognosis of laryngeal squamous cell carcinoma. Med Oncol. 2012; 29: 2466-2472.
46. Ni S, Xu L, Huang J, Feng J, Zhu H, Wang G, Wang X. Increased ZO-1 expression predicts valuable prognosis in non-small cell lung cancer. Int J Clin Exp Path. 2013; 6:2887-2895.
47. Zhai X, Zhu H, Wang W, Zhang S, Zhang Y, Mao G. Abnormal expression of EMT-related proteins, S100A4, vimentin and E-cadherin, is correlated with clinicopathological features and prognosis in HCC. Med Oncol. 2014; 31:970.
48. Wang Y, Chen D, Qian H, Tsai YS, Shao S, Liu Q, Dominguez Dang Wang Z. The Splicing Factor RBM4 Controls Apoptosis, Proliferation, and Migration to Suppress Tumor Progression. Cancer Cell. 2014; 26: 374-89.